We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Differential Gene Expression Found in Normal and Hypertensive Kidneys

By LabMedica International staff writers
Posted on 22 Nov 2011
In a comparison of gene expression in kidney tissues isolated from patients with hypertension and controls with normal blood pressure researchers found 14 genes and 11 miRNAs (microRNAs) that were differentially expressed in the medulla.

Investigators at the University of Leicester (United Kingdom) and colleagues from Poland and Australia analyzed tissue samples selected from 15 patients known to have high blood pressure, along with seven patients with normal blood pressure who were used as the control group for the study. More...
The samples of human kidneys were stored in the Silesian Renal Tissue Bank (SRTB), and came from Polish males, individuals of white European ancestry.

Results of microarray analysis published in the October 31, 2011, online edition of the journal Hypertension revealed 14 genes and 11 miRNAs that were differentially expressed in the kidney medulla. Two of the miRNAs, which had lower levels of expression in the tissues from the hypertension patients, were linked to renin expression. Inhibition of miRNAs that reduce renin synthesis causes increased expression of renin activity. An overactive renin-angiotension system leads to vasoconstriction and retention of sodium and water. These effects lead to hypertension.

“I am very excited about this publication,” said contributing author Dr. Maciej Tomaszewski, senior clinical lecturer in cardiovascular medicine at the University of Leicester. “Renin is one of the most important contributors to blood pressure regulation. The novel insights into its expression within the human kidney from this study open up new avenues for the development of new antihypertensive medications. The collection of hypertensive and normotensive kidneys is available for our studies in Leicester thanks to a long-term international collaboration. We will continue using this unique research resource in our further studies to decipher the genetic background of human hypertension.”

Related Links:
University of Leicester




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
All-in-One Molecular System
AIO M160
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.